SCHEMBL8385134

SCHEMBL8385134

CCCCCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 7/20 1.00
KMT2A Q03164 3/20 0.96
MEN1 O00255 2/20 0.96
MAPK1 P28482 2/20 0.96
SMN1; SMN2 Q16637 2/20 0.96
TP53 P04637 1/20 0.96
HTT P42858 5/20 0.93
HSP90AA1 P07900 2/20 0.67
RAD52 P43351 2/20 0.67
PSMD14 O00487 1/20 0.67
MMP2 P08253 1/20 0.67
MC4R P32245 1/20 0.67
MLNR O43193 1/20 0.56
NR1I2 O75469 1/20 0.56
ESR1 P03372 1/20 0.56
NR3C1 P04150 1/20 0.56
PGR P06401 1/20 0.56
ADRB2 P07550 1/20 0.56
CHRM2 P08172 1/20 0.56
ADRB1 P08588 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL297265 1.00 DNM1 (1.00) DNM1KMT2AMEN1MAPK1SMN1; SMN2
Benzododecinium SCHEMBL153696 1.00 DNM1 (1.00) DNM1KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL8385144 1.00 DNM1 (1.00) DNM1KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL8386100 1.00 DNM1 (1.00) DNM1KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL8387572 1.00 DNM1 (1.00) DNM1KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL8382110 1.00 DNM1 (1.00) DNM1KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL25240887 1.00 DNM1 (1.00) DNM1KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL640153 1.00 DNM1 (1.00) DNM1KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL10810481 1.00 DNM1 (1.00) DNM1KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL8386218 1.00 DNM1 (1.00) DNM1KMT2AMEN1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4146765-B1 A METHOD AND REAGENTS FOR ENHANCING THE CHEMILUMINESCENT SIGNAL EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) 2023-07-05 EP claimed
EP-0707489-A4 ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF SCOTGEN BIOPHARMACEUTICALS INC (US) 1998-07-29 EP claimed
EP-0707489-A1 ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF Scotgen Biopharmaceuticals, Inc. (US) 1996-04-24 EP claimed
WO-1994025053-A1 ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF SCOTGEN BIOPHARMACEUTICALS, INC. (US) 1994-11-10 WO claimed
US-20240353412-A1 A METHOD AND REAGENTS FOR ENHANCING THE CHEMILUMINESCENT SIGNAL EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) 2024-10-24 US disclosed
EP-4146765-B1 A METHOD AND REAGENTS FOR ENHANCING THE CHEMILUMINESCENT SIGNAL EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) 2023-07-05 EP disclosed
US-5955584-A NON-PROTEIN ANTIGEN COMPOSED OF STEROID COMPONENT WITH 3 BETA HYDROXY OR 3 KETO GROUP AND QUATERNARY AMMONIUM SALT; FOR THERAPY AND IMMUNOASSAY DIAGNOSIS CHARTER VENTURES (US) 1999-09-21 US disclosed
US-5811248-A Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof CHARTER VENTURES (US) 1998-09-22 US disclosed
EP-0707489-A4 ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF SCOTGEN BIOPHARMACEUTICALS INC (US) 1998-07-29 EP disclosed
EP-0707489-A1 ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF Scotgen Biopharmaceuticals, Inc. (US) 1996-04-24 EP disclosed
WO-1994025053-A1 ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF SCOTGEN BIOPHARMACEUTICALS, INC. (US) 1994-11-10 WO disclosed